Posted by Michael Wonder on 26 Mar 2019
Health Canada approves Cimzia (certolizumab pegol) for moderate-to-severe psoriasis
25 March 2019 - Health Canada also approves label updates in pregnancy and breast-feeding
UCB Canada announced today that Health Canada has approved a new indication for Cimzia (certolizumab pegol) for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy.
The approval makes Cimzia the first Fc-free, PEGylated anti-TNF option available for the treatment of the disease where significant unmet need currently exists. UCB Canada also announced that Health Canada has approved label updates in pregnancy and breastfeeding based on two pivotal pharmacokinetic studies. This marks a major advance for Canadian women of all ages living with plaque psoriasis and other auto-immune diseases.
